In a groundbreaking study poised to reshape acute heart failure management, researchers have unveiled compelling evidence that combining intravenous furosemide with small-volume hypertonic saline solution (HSS) significantly alters inflammatory markers and epigenetic signatures in patients suffering from acute decompensated heart failure (ADHF). This innovative randomized trial, led by Mario Daidone and Antonino Tuttolomondo at the University Hospital Policlinico Paolo Giaccone and the University of Palermo, represents a critical advance in understanding how adjunct therapies could modulate the pathophysiological environment of the failing heart at a molecular level.
Acute decompensated heart failure is a life-threatening condition characterized by sudden worsening of symptoms due to impaired left ventricular function and systemic congestion. Loop diuretics like furosemide remain standard treatment to relieve fluid overload; however, their long-term effect on inflammation, cardiac remodeling, and epigenetic regulation in ADHF has remained elusive. In this study, the therapeutic potential of supplementing intravenous furosemide with a hypertonic saline solution was rigorously evaluated for its impact on a spectrum of inflammatory and remodeling biomarkers as well as microRNA (miRNA) expression profiles, which serve as critical epigenetic regulators of gene expression.
The researchers enrolled 200 patients diagnosed with ADHF attributable to reduced ejection fraction and randomized them into two groups: one receiving standard intravenous furosemide therapy and the other receiving combined intravenous furosemide plus small-volume hypertonic saline solution. Over the course of treatment, serial serum assessments were conducted to measure canonical biomarkers including interleukin-6 (IL-6), soluble suppression of tumorigenicity 2 (sST2), high-sensitivity troponin T (hsTnT), galectin-3, and N-terminal pro b-type natriuretic peptide (NT-proBNP), all of which correlate with inflammation, myocardial injury, fibrosis, and cardiac stress.
The study revealed a noteworthy attenuation in the serum increase of these markers in patients treated with furosemide plus hypertonic saline relative to those receiving furosemide monotherapy. IL-6, a pro-inflammatory cytokine intricately involved in myocardial inflammation, showed reduced elevation, suggesting a dampened systemic inflammatory response. Similarly, the reduction in sST2—a marker linked to cardiac fibrosis and remodeling—implied mitigation of maladaptive myocardial remodeling processes. Decreases in hsTnT and galectin-3 further underscored the cardioprotective effect of the combined treatment in limiting myocardial injury and fibrosis.
Importantly, the addition of hypertonic saline was associated with modulation of specific microRNAs, particularly miR-181b, which was significantly downregulated compared to standard therapy. MicroRNAs function as crucial epigenetic modulators capable of regulating gene networks involved in inflammation and cardiac remodeling. The observed miRNA expression shift suggests that the therapeutic effect extends beyond biochemical attenuation to influence the epigenetic landscape governing the disease process.
The mechanism by which hypertonic saline exerts these benefits appears multifactorial. By correcting hyponatremia and modulating intravascular volume more precisely, small-volume hypertonic saline may improve renal perfusion and enhance natriuresis when combined with furosemide, thereby reducing neurohormonal activation and inflammatory cascade amplification. The unique ionic environment also may influence cellular signaling pathways involved in fibroblast activation and cardiomyocyte stress responses, yielding less pathological remodeling.
Despite the promising findings, the investigators caution that further studies with longer follow-up and diverse patient populations are needed to verify the durability and clinical relevance of these molecular changes. Determining how modulation of inflammatory biomarkers and miRNA signatures translates into improved functional outcomes and survival remains a critical next step. Moreover, elucidating the precise molecular targets of hypertonic saline in the heart and other organs will deepen understanding of its therapeutic role.
The study’s randomized design and relatively large sample size lend robustness to the data, yet limitations include the single-center setting and focus exclusively on patients with reduced ejection fraction ADHF, which may limit generalizability. Future research extending to preserved ejection fraction heart failure and exploring dose optimization of hypertonic saline will be essential for refining clinical guidelines.
This therapeutic strategy, by integrating traditional loop diuretic treatment with a modulator of the ionic and epigenetic milieu, opens novel avenues in heart failure management centered on targeted modulation of the inflammatory and remodeling cascade. If validated in larger clinical trials, this approach could not only improve symptomatic management but potentially alter disease trajectory by influencing underlying molecular drivers.
The implications for clinical practice are profound, offering a precision medicine approach to treating ADHF that harnesses both pharmacologic and epigenetic insights. As heart failure continues to impose a substantial global health burden, innovations like this combined furosemide and hypertonic saline regimen provide hope for improved outcomes through multidimensional molecular modulation.
In conclusion, the study presents pioneering evidence that the co-administration of intravenous furosemide and small-volume hypertonic saline solution can favorably influence inflammatory, remodeling, and epigenetic markers in acute decompensated heart failure. This dual-modality intervention holds promise for more effective therapeutic strategies that extend beyond symptomatic relief to molecular reprogramming of pathological processes underlying heart failure progression.
Subject of Research: People
Article Title: Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF)
News Publication Date: 26-Mar-2026
Web References:
https://doi.org/10.18632/aging.206364
https://www.aging-us.com/issue/v18i1/
Image Credits: Copyright: © 2026 Daidone et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
Keywords: aging, heart failure, acute decompensated heart failure, furosemide, hypertonic saline solution
